NextCell Pharma Q3 2024/2025: Largely as expected - Redeye
Bildkälla: Stockfoto

NextCell Pharma Q3 2024/2025: Largely as expected - Redeye

Redeye provides an update on NextCell following the company’s Q3 report, which came in largely in line with expectations. While 2025 has been a turbulent year so far, the storm is now largely weathered. With a modest valuation and secured funding that covers upcoming potential value inflection points, we reiterate our fair value range.

Redeye provides an update on NextCell following the company’s Q3 report, which came in largely in line with expectations. While 2025 has been a turbulent year so far, the storm is now largely weathered. With a modest valuation and secured funding that covers upcoming potential value inflection points, we reiterate our fair value range.
Börsvärldens nyhetsbrev